Abbott, Ascensia Diabetes Care Holdings AG and BD are Dominating the Global At-Home Testing Kits Market in 2020

Global At-Home Testing Kits Market is expected to grow with the CAGR of 5.3% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-at-home-testing-kits-market

Global at-home testing kits market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global at-home testing kits market are introducing strong range of service portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In December 2020, Eurofins Viracor, Inc. announced that they have launched a combined test for COVID-19, Influenza and RSV taking concern of the upcoming season for flu and other infections in the U.S. region. This launch was on 7th December and will enhance the product portfolio for the company and increase the revenue for the company.

Abbott is the dominating player in global at-home testing kits market. The other key players existing in the market includes ACON Laboratories, Inc., Ascensia Diabetes Care Holdings AG, Rapikit, BTNX INC., bioLytical Laboratories Inc., OraSure Technologies, Inc., BD, Cardinal Health, B. Braun Melsungen AG, Piramal Enterprises Ltd., PRIMA Lab SA, Siemens Healthcare GmbH, Quidel Corporation, Bionime Corporation, SA Scientific, ARKRAY USA, Inc., Everlywell, Inc., Nova Biomedical, Eurofins Viracor, Inc. , SelfDiagnostics OU, AdvaCare Pharma, AccuBio Tech Co., Ltd, BioSure UK, Atlas Medical UK, TaiDoc Technology Corporation, LifeScan IP Holdings, LLC, Chembio Diagnostics, Inc., Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd., Biosynex, Sensing Self, PTE. Ltd, Atomo Diagnostics, RUNBIO BIOTECH CO.,LTD, Clearblue (A Subsidiary of Clear Blue Technologies International Inc), Sterilab Services, Mylan N.V. (A Subsidiary of Viatris Inc), MP BIOMEDICALS and VedaLab among others.

At-Home Testing Kits MarketAbbott

Abbott headquartered in Illinois, U.S. which was established in 1900. The company is engaged in manufacturing and providing healthcare products such as medical devices, diagnostic products and nutritional products for consumers. The company offers wide range of product categories such as consumer & healthcare professional among which consumer are focused category. The company operates their business through established pharmaceutical products, diagnostic products, nutritional products and medical devices while diagnostic products is focused category.

  • In December 2020, Abbott has introduced new BinaxNOW rapid test for testing COVID-19 virus at home and at very low cost and it provides results in minutes and detects the virus in the early part of the infection and disease. This new launched rapid test kit will help company to acquire more customers and increase their business.

The company has wide global presence across the globe such as North America, South America, Europe, Middle East and Africa, Asia-Pacific. In addition to it, the company also generates its revenue from the various subsidiary companies such as Abbott Administration Inc. (U.S.), Abbott Diabetes Care Inc. (U.S.), Abbott Laboratories Argentina S.A. (Argentina), Abbott Australasia Pty Ltd (Australia) and others.

Ascensia Diabetes Care Holdings AG

Ascensia Diabetes Care Holdings AG headquartered in Basel, Switzerland was founded in year 2016. The company offers wide range of products and solutions related to diabetes and serve the needs of their patients through innovations and expertise. The company offers wide range of product categories contour next blood glucose monitoring systems, contour plus blood glucose monitoring systems and diabetes management solutions among which contour next blood glucose monitoring systems and contour plus blood glucose monitoring systems is market focused category.

  • In August 2020, Ascensia Diabetes Care Holdings AG and its parent company PHC Holdings Corporation announced that they have entered into a strategic partnership with Senseonics Holdings, Inc. which is a medical technology company who are focused on development and commercialization of continuous glucose monitoring (CGM) systems. PHC Holdings Corporation has made an initial investment of USD 35.00 million. It will help the company to further improve their product offerings as well as leverage the huge customer base of Senseonics Holdings, Inc.

The company has presence in Americas, Asia-Pacific, Europe, Middle East and Africa.

BD

BD is headquartered in New Jersey, U.S. which was founded in 1906. The company is engaged in providing innovative solutions related to medical research, diagnosis of infectious disease and cancer, infection prevention, surgical equipment. The company has product categories which are anesthia delivery, biopsy, biosceicne, bio surgery, cervical cancer screening, diabetes, drainage, hazardous drug safety, home care, infection prevention, infusion therapy, interventional specialities, lab automation, medication and supply management, microbiology solutions, molecular diagnostics, patient monitoring and temperature management, prostate health, sharps disposal solutions, software solutions, surgical instruments, syringes and needles, urology and kidney health, vascular access, wound care in which microbiology solutions is market focused category. The company has various business segments medical, life sciences and interventional among which market focused segment is medical.

  • In June 2020, BD, a leading global medical technology company has announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company will add the valuable expertise and experience of Straub Medical AG and will expand their product portfolio.

The company has global presence in Americas, Europe, Middle East and Africa, Asia-Pacific. In addition, company also generates revenue through the subsidiary such as Atto BioScience, Inc. (U.S.), BD Holding S. de R.L. de C.V. (Mexico), BD Norge AS (Norway), Becton Dickinson Argentina S.R.L. (Aregntina), Becton Dickinson Asia Limited (Hong Kong) among others.